# Light & Wonder, Inc.: financial statements, quarterly

LAWIL · OTC · CIK 750004 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lawil.md) · [Financials](/companies/lawil/financials.md) · [Filings](/companies/lawil/filings.md) · [Insiders](/companies/lawil/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lawil/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [731](/filings/0000750004-24-000064.md) | [771 d](/filings/0000750004-26-000012.md) | [756](/filings/0000750004-25-000031.md) | [818](/filings/0000750004-25-000048.md) | [817](/filings/0000750004-25-000072.md) | [797 d](/filings/0000750004-26-000012.md) | [774](/filings/0000750004-26-000022.md) | [809](/filings/0000750004-26-000033.md) | [841](/filings/0000750004-25-000072.md) | [890 d](/filings/0000750004-26-000012.md) | [790](/filings/0000750004-26-000022.md) | [828](/filings/0000750004-26-000033.md) |
| Cost of revenue | $m | not reported | not reported | [219](/filings/0000750004-25-000031.md) | [236](/filings/0000750004-25-000048.md) | [246](/filings/0000750004-25-000072.md) | [230 d](/filings/0000750004-26-000012.md) | [211](/filings/0000750004-26-000022.md) | [219](/filings/0000750004-26-000033.md) | [217](/filings/0000750004-25-000072.md) | [238 d](/filings/0000750004-26-000012.md) | [194](/filings/0000750004-26-000022.md) | [210](/filings/0000750004-26-000033.md) |
| Research and development | $m | [55.0](/filings/0000750004-24-000064.md) | [60.0 d](/filings/0000750004-26-000012.md) | [62.0](/filings/0000750004-25-000031.md) | [66.0](/filings/0000750004-25-000048.md) | [66.0](/filings/0000750004-25-000072.md) | [68.0 d](/filings/0000750004-26-000012.md) | [65.0](/filings/0000750004-26-000022.md) | [64.0](/filings/0000750004-26-000033.md) | [62.0](/filings/0000750004-25-000072.md) | [60.0 d](/filings/0000750004-26-000012.md) | [67.0](/filings/0000750004-26-000022.md) | [61.0](/filings/0000750004-26-000033.md) |
| Selling, general and administrative | $m | [204](/filings/0000750004-24-000064.md) | [209 d](/filings/0000750004-26-000012.md) | [218](/filings/0000750004-25-000031.md) | [220](/filings/0000750004-25-000048.md) | [220](/filings/0000750004-25-000072.md) | [215 d](/filings/0000750004-26-000012.md) | [217](/filings/0000750004-26-000022.md) | [208](/filings/0000750004-26-000033.md) | [219](/filings/0000750004-25-000072.md) | [225 d](/filings/0000750004-26-000012.md) | [237](/filings/0000750004-26-000022.md) | [211](/filings/0000750004-26-000033.md) |
| Operating income | $m | [147](/filings/0000750004-24-000064.md) | [156 d](/filings/0000750004-26-000012.md) | [165](/filings/0000750004-25-000031.md) | [175](/filings/0000750004-25-000048.md) | [159](/filings/0000750004-25-000072.md) | [168 d](/filings/0000750004-26-000012.md) | [170](/filings/0000750004-26-000022.md) | [202](/filings/0000750004-26-000033.md) | [229](/filings/0000750004-25-000072.md) | [83.0 d](/filings/0000750004-26-000012.md) | [130](/filings/0000750004-26-000022.md) | [223](/filings/0000750004-26-000033.md) |
| Interest expense | $m | [78.0](/filings/0000750004-23-000049.md) | [78.0 d](/filings/0000750004-26-000012.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [14.0](/filings/0000750004-24-000064.md) | [(2.0) d](/filings/0000750004-26-000012.md) | [18.0](/filings/0000750004-25-000031.md) | [26.0](/filings/0000750004-25-000048.md) | [17.0](/filings/0000750004-25-000072.md) | [24.0 d](/filings/0000750004-26-000012.md) | [23.0](/filings/0000750004-26-000022.md) | [29.0](/filings/0000750004-26-000033.md) | [25.0](/filings/0000750004-25-000072.md) | [13.0 d](/filings/0000750004-26-000012.md) | [10.0](/filings/0000750004-26-000022.md) | [30.0](/filings/0000750004-26-000033.md) |
| Net income | $m | [75.0](/filings/0000750004-24-000064.md) | [67.0 d](/filings/0000750004-26-000012.md) | [82.0](/filings/0000750004-24-000028.md) | [82.0](/filings/0000750004-24-000045.md) | [64.0](/filings/0000750004-24-000064.md) | [108 d](/filings/0000750004-26-000012.md) | [82.0](/filings/0000750004-26-000033.md) | [95.0](/filings/0000750004-26-000033.md) | [114](/filings/0000750004-25-000072.md) | [(15.0) d](/filings/0000750004-26-000012.md) | [52.0](/filings/0000750004-26-000033.md) | [120](/filings/0000750004-26-000033.md) |
| Diluted EPS | $ per share | [0.81](/filings/0000750004-24-000064.md) | not reported | [0.88](/filings/0000750004-25-000031.md) | [0.90](/filings/0000750004-25-000048.md) | [0.71](/filings/0000750004-25-000072.md) | not reported | [0.94](/filings/0000750004-26-000022.md) | [1.11](/filings/0000750004-26-000033.md) | [1.34](/filings/0000750004-25-000072.md) | not reported | [0.66](/filings/0000750004-26-000022.md) | [1.53](/filings/0000750004-26-000033.md) |
| Basic EPS | $ per share | [0.83](/filings/0000750004-24-000064.md) | not reported | [0.91](/filings/0000750004-25-000031.md) | [0.92](/filings/0000750004-25-000048.md) | [0.72](/filings/0000750004-25-000072.md) | not reported | [0.97](/filings/0000750004-26-000022.md) | [1.12](/filings/0000750004-26-000033.md) | [1.37](/filings/0000750004-25-000072.md) | not reported | [0.68](/filings/0000750004-26-000022.md) | [1.55](/filings/0000750004-26-000033.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [891](/filings/0000750004-23-000049.md) | [425](/filings/0000750004-25-000016.md) | [450](/filings/0000750004-24-000028.md) | [321](/filings/0000750004-24-000045.md) | [347](/filings/0000750004-24-000064.md) | [196](/filings/0000750004-26-000012.md) | [134](/filings/0000750004-25-000031.md) | [136](/filings/0000750004-25-000048.md) | [236](/filings/0000750004-25-000072.md) | [167](/filings/0000750004-26-000033.md) | [147](/filings/0000750004-26-000022.md) | [148](/filings/0000750004-26-000033.md) |
| Current assets | $m | [1,720](/filings/0000750004-23-000049.md) | [1,311](/filings/0000750004-25-000016.md) | [1,340](/filings/0000750004-24-000028.md) | [1,289](/filings/0000750004-24-000045.md) | [1,279](/filings/0000750004-24-000064.md) | [1,183](/filings/0000750004-26-000012.md) | [1,184](/filings/0000750004-25-000031.md) | [1,237](/filings/0000750004-25-000048.md) | [1,322](/filings/0000750004-25-000072.md) | [1,283](/filings/0000750004-26-000033.md) | [1,205](/filings/0000750004-26-000022.md) | [1,240](/filings/0000750004-26-000033.md) |
| Total assets | $m | [5,887](/filings/0000750004-23-000049.md) | [5,552](/filings/0000750004-25-000016.md) | [5,588](/filings/0000750004-24-000028.md) | [5,538](/filings/0000750004-24-000045.md) | [5,596](/filings/0000750004-24-000064.md) | [5,421](/filings/0000750004-26-000012.md) | [5,455](/filings/0000750004-25-000031.md) | [6,490](/filings/0000750004-25-000048.md) | [6,509](/filings/0000750004-25-000072.md) | [6,462](/filings/0000750004-26-000033.md) | [6,365](/filings/0000750004-26-000022.md) | [6,364](/filings/0000750004-26-000033.md) |
| Current liabilities | $m | [619](/filings/0000750004-23-000049.md) | [696](/filings/0000750004-25-000016.md) | [677](/filings/0000750004-24-000028.md) | [696](/filings/0000750004-24-000045.md) | [680](/filings/0000750004-24-000064.md) | [735](/filings/0000750004-26-000012.md) | [753](/filings/0000750004-25-000031.md) | [697](/filings/0000750004-25-000048.md) | [621](/filings/0000750004-25-000072.md) | [803](/filings/0000750004-26-000033.md) | [676](/filings/0000750004-26-000022.md) | [715](/filings/0000750004-26-000033.md) |
| Total liabilities | $m | [4,741](/filings/0000750004-23-000049.md) | [4,787](/filings/0000750004-25-000016.md) | [4,753](/filings/0000750004-24-000028.md) | [4,752](/filings/0000750004-24-000045.md) | [4,738](/filings/0000750004-24-000064.md) | [4,785](/filings/0000750004-26-000012.md) | [4,835](/filings/0000750004-25-000031.md) | [5,788](/filings/0000750004-25-000048.md) | [5,786](/filings/0000750004-25-000072.md) | [6,217](/filings/0000750004-26-000033.md) | [6,054](/filings/0000750004-26-000022.md) | [6,062](/filings/0000750004-26-000033.md) |
| Current portion of debt | $m | [22.0](/filings/0000750004-23-000049.md) | [22.0](/filings/0000750004-25-000016.md) | [22.0](/filings/0000750004-24-000028.md) | [22.0](/filings/0000750004-24-000045.md) | [23.0](/filings/0000750004-24-000064.md) | [23.0](/filings/0000750004-26-000012.md) | [23.0](/filings/0000750004-25-000031.md) | [38.0](/filings/0000750004-25-000048.md) | [49.0](/filings/0000750004-25-000072.md) | [53.0](/filings/0000750004-26-000033.md) | [58.0](/filings/0000750004-26-000022.md) | [63.0](/filings/0000750004-26-000033.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [959](/filings/0000750004-23-000049.md) | [765](/filings/0000750004-24-000015.md) | [835](/filings/0000750004-25-000072.md) | [786](/filings/0000750004-25-000072.md) | [858](/filings/0000750004-25-000072.md) | [636](/filings/0000750004-26-000033.md) | [620](/filings/0000750004-26-000033.md) | [702](/filings/0000750004-26-000033.md) | [723](/filings/0000750004-25-000072.md) | [245](/filings/0000750004-26-000033.md) | [311](/filings/0000750004-26-000033.md) | [302](/filings/0000750004-26-000033.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: us-gaap:DebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [204 d](/filings/0000750004-24-000064.md) | [167 d](/filings/0000750004-26-000012.md) | [171](/filings/0000750004-25-000031.md) | [141 d](/filings/0000750004-25-000048.md) | [118 d](/filings/0000750004-25-000072.md) | [202 d](/filings/0000750004-26-000012.md) | [185](/filings/0000750004-26-000022.md) | [106 d](/filings/0000750004-26-000033.md) | [184 d](/filings/0000750004-25-000072.md) | [319 d](/filings/0000750004-26-000012.md) | [139](/filings/0000750004-26-000022.md) | [241 d](/filings/0000750004-26-000033.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | [61.0](/filings/0000750004-26-000022.md) | [78.0 d](/filings/0000750004-26-000033.md) | not reported | not reported | [74.0](/filings/0000750004-26-000022.md) | [83.0 d](/filings/0000750004-26-000033.md) |
| Share repurchases | $m | [112 d](/filings/0000750004-24-000064.md) | [25.0 d](/filings/0000750004-26-000012.md) | [25.0](/filings/0000750004-25-000031.md) | [150 d](/filings/0000750004-25-000048.md) | [44.0 d](/filings/0000750004-25-000072.md) | [243 d](/filings/0000750004-26-000012.md) | [166](/filings/0000750004-26-000022.md) | [104 d](/filings/0000750004-26-000033.md) | [110 d](/filings/0000750004-25-000072.md) | [500 d](/filings/0000750004-26-000012.md) | [22.0](/filings/0000750004-26-000022.md) | [141 d](/filings/0000750004-26-000033.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [96.0](/filings/0000750004-23-000049.md) | [93.0](/filings/0000750004-24-000028.md) | [91.0](/filings/0000750004-24-000045.md) | [92.0](/filings/0000750004-24-000064.md) | [92.0](/filings/0000750004-25-000031.md) | [92.0](/filings/0000750004-25-000048.md) | [91.0](/filings/0000750004-25-000072.md) | [86.9](/filings/0000750004-26-000022.md) | [85.6](/filings/0000750004-26-000033.md) | [85.0](/filings/0000750004-25-000072.md) | [79.2](/filings/0000750004-26-000022.md) | [78.5](/filings/0000750004-26-000033.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 77,049,181 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0000750004-26-000033.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.